Considerations for Complying with 21 CFR 211110
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
January 6, 2025
January 6, 2025
3d80c8ad-a552-4ac0-9f33-3581f781f0c3
Related Documents
Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products
Guidance DocumentMarch 21, 2024Center for Drug Evaluation and Research
Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities
Guidance DocumentOctober 26, 2023Center for Drug Evaluation and Research
Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products
Guidance DocumentFebruary 1, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox